SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$41.44 USD
+0.08 (0.19%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $41.70 +0.26 (0.63%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SWTX 41.44 +0.08(0.19%)
Will SWTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SWTX
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
Other News for SWTX
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Springworks Therapeutics (SWTX) and SAGE Therapeutics (SAGE)
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)
Immunome: AL102 And Other Established Protein Targets Could Drive Value
SpringWorks Therapeutics (SWTX) Shares Cross Below 200 DMA